CTMX Q2 2023 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M+92.4% YoY

Gross Profit

$23M93.8% margin

Operating Income

-$3M-13.5% margin

Net Income

-$1M-4.4% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+5.2%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$26M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$209M

Total Liabilities

$294M

Stockholders' Equity

-$85M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$13M	+92.4%
Gross Profit	$23M	$13M	+80.4%
Operating Income	-$3M	-$30M	+88.9%
Net Income	-$1M	-$29M	+96.3%